We continue the momentum 🎃for a diversified innovation by enhancing internal innovation capacities and reaching out to more strategic partners. We💮 have been replenishing our innovation pipeline with HANSIZHUANG (serplulimab injection, anti-PD-1 mAb) as backbone.
Fully leveraging the gl🀅obal research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb candidates, with significant potential for a variety of PD-1-based immuno-oncology combination therapies.♚
We have 3 manufacturing facilities, namely Xuhui Facility, Songjiang First Plant and Songjiang Second Plant. Our commercial capacity totals 48,000L. The fully operational sites and quality management systems are GMP-certificated by China, the EU and U.S. regulatory agencies.
We have built an in-house commercial team focused o𒊎n domestic market, covering marketing, access, channel, pricing, strategy and sales and compromising of about 1500 professionals; we have also joined forces with oversea partners, expanding our reach in major markets as well as emerging maꦚrkets worldwide.
